Drug and Alcohol Dependence
Volume 67, Issue 1 , Pages 73-79 , 1 June 2002

Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine

  • Brian M. Ross

      Affiliations

    • Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ont., Canada M5T 1R8
    • ,
  • Anna Moszczynska

      Affiliations

    • Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ont., Canada M5T 1R8
    • ,
  • Frank J. Peretti

      Affiliations

    • Arkansas State Crime Laboratory, Little Rock, AR, USA
    • ,
  • Vernard Adams

      Affiliations

    • Office of the Hillsborough County Medical Examiner, Tampa, FL, USA
    • ,
  • Gregory A. Schmunk

      Affiliations

    • Santa Clara County Medical Examiner-Coroner San Jose, CA, USA
    • ,
  • Kathryn S. Kalasinsky

      Affiliations

    • Division of Forensic Toxicology, Office of the Armed Forces Medical Examiner, Armed Forces Institute of Pathology, Washington, DC, USA
    • ,
  • Lee Ang

      Affiliations

    • Department of Pathology (Neuropathology), London Health Sciences Centre, London, Ont., Canada
    • ,
  • Nikolaos Mamalias

      Affiliations

    • Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ont., Canada M5T 1R8
    • ,
  • Sylvie D. Turenne

      Affiliations

    • Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ont., Canada M5T 1R8
    • ,
  • Stephen J. Kish

      Affiliations

    • Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ont., Canada M5T 1R8
    • Corresponding Author InformationCorresponding author. Tel.: +1-416-535-8501x6256; fax: +1-416-979-6871

Received 12 October 2001 ,Revised 8 February 2002 ,Accepted 14 February 2002.

References 

  1. Hayakawa T, Chang MC, Bell JM, Seeman R, Rapoport SI, Appel NM. Fatty acid incorporation depicts brain activity in a rat model of Parkinson's disease. Brain Res. 1998;807:177–181
  2. Hussain T, Lokhandwala MF. Dopamine-1 receptor G-protein coupling and the involvement of phospholipase A2 in dopamine-1 receptor mediated cellular signaling mechanisms in the proximal tubules of SHR. Clin. Exp. Hypertens. 1997;19:131–140
  3. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res. Rev. 1999;31:6–41
  4. Ingram SL, Amara SG. Arachidonic acid stimulates a novel cocaine-sensitive cation conductance associated with the human dopamine transporter. J. Neurosci. 2000;15:550–557
  5. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. New Engl. J. Med. 1988;318:876–880
  6. Lopez G, Coviella I, Agut J, Ortiz JA, Wurtman RJ. Effects of orally administered cytidine 5′-diphosphate choline on brain phospholipid content. J. Nutr. Biochem. 1992;3:313–315
  7. MacKay S, Meyerhoff DJ, Dillon WP, Weiner MW, Fein G. Alteration of brain phospholipid metabolites in cocaine-dependent polysubstance abusers. Biol. Psychiat. 1993;34:261–264
  8. Martinet M, Fonlupt P, Pacheco H. Activation of soluble striatal tyrosine hydroxylase in the rat brain after CDP choline administration. Biochem. Pharmacol. 1981;30:539–541
  9. Mayer RJ, Marshall LA. New insights on mammalian phospholipase A2(s); comparison of arachidonyl-selective and -nonselective enzymes. FASEB J. 1993;7:339–348
  10. McAllister G, Knowles MR, Patel S, Marwood R, Emms F, Seabrook GR, et al. Characterization of a chimeric D3/D2 dopamine receptor expressed in CHO cells. FEBS Letts. 1993;324:81–86
  11. Nielsen JA, Sparber SB. Indomethacin potentiates the operant behavior suppressant and rectal temperature lowering effects of low doses of d-amphetamine in rats. Pharm. Biochem. Behav. 1984;21:219–224
  12. Nilsson CL, Hellstrand M, Ekman A, Eriksson E. Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent. Br. J. Pharmacol. 1998;124:1651–1658
  13. Reid MS, Hsu K, Tolliver BK, Crawford CA, Berger SP. Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitisation. J. Pharm. Exp. Ther. 1996;276:1244–1256
  14. Renshaw PF, Daniels S, Lundahl LH, Rogers V, Lukas SE. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology (Berl.). 1999;142:132–138
  15. Ross BM, Kish SJ. Characterization of lysophospholipid metabolizing enzymes in human brain. J. Neurochem. 1994;63:1839–1848
  16. Ross BM, Kim DK, Bonventre JV, Kish SJ. Characterization of a novel phospholipase A2 activity in human brain. J. Neurochem. 1995;64:2213–2221
  17. Ross BM, Sherwin AL, Kish SJ. Multiple forms of the enzyme glycerophosphodiesterase are present in human brain. Lipids. 1995;30:1075–1081
  18. Ross BM, Moszczynska A, Kalasinsky K, Kish SJ. Phospholipase A2 activity is selectively decreased in the striatum of chronic cocaine users. J. Neurochem. 1996;67:2620–2623
  19. Ross BM, Moszczynska A, Blusztajn JK, Sherwin A, Lozano A, Kish SJ. Phospholipid biosynthetic enzymes in human brain. Lipids. 1997;32:351–358
  20. Ross BM, Moszczynska A, Erlich J, Kish SJ. Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: possible implications for Parkinson's disease. Neuroscience. 1998;83:791–798
  21. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Meth. Find Exp. Clin. Pharmacol. 1995;(Suppl. B):2–54
  22. Smith WL, Borgeat P, Fitzpatrick FA. The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathways. In:  Vance DE,  Vance J editor. Biochemistry of Lipids, Lipoproteins and Membranes. Amsterdam: Elsevier; 1991;p. 297–325
  23. Tolliver BK, Ho LB, Fox LM, Berger SP. Necessary role for ventral tegmental area adenylate cyclase and protein kinase A in induction of behavioral sensitization to intraventral tegmental area amphetamine. J. Pharmacol. Exp. Ther. 1999;289:38–47
  24. Vial D, Piomelli D. Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonic-specific phospholipase A2. J. Neurochem. 1995;64:2765–2772
  25. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996;2:699–703
  26. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 1996;40:428–439

☆ The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting views of the United States Department of Army or Department of Defense.

PII: S0376-8716(02)00022-4

Drug and Alcohol Dependence
Volume 67, Issue 1 , Pages 73-79 , 1 June 2002

Article Tools

* Image Usage & Resolution